Human antibody cocktail deploys multiple functions to confer pan-ebolavirus protection
During the unprecedented 2013–2016 Ebola virus disease (EVD) epidemic in Western Africa and in its aftermath, the passive administration of monoclonal antibodies (mAbs) emerged as a promising treatment approach1–7. However, all antibody-based therapeutics currently in advanced development are specific for a single member of the Ebolavirus genus, Ebola virus (EBOV), and ineffective against divergent outbreak-causing ebolaviruses, including Bundibugyo virus (BDBV) and Sudan virus (SUDV)2,3,5,7. Here we advance MBP134, a cocktail of two broadly neutralizing human mAbs targeting the filovirus surface glycoprotein, GP, as a candidate pan-ebolavirus therapeutic. One component of this cocktail is a pan-ebolavirus neutralizing mAb, ADI-15878, isolated from a human EVD survivor8,9. The second, ADI-23774, was derived by affinity maturation of a human mAb8,9 via yeast display to enhance its potency against SUDV. MBP134 afforded exceptionally potent pan-ebolavirus neutralization in vitro and demonstrated greater protective efficacy than ADI-15878 alone in the guinea pig model of lethal EBOV challenge. A second-generation cocktail, MBP134AF, engineered to effectively harness natural killer (NK) cells afforded additional, unprecedented improvements in protective efficacy against EBOV and SUDV in guinea pigs relative to both its precursor and to any mAbs or mAb cocktails tested previously. MBP134AF is a best-in-class mAb cocktail suitable for evaluation as a pan-ebolavirus therapeutic in nonhuman primates..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
bioRxiv.org - (2020) vom: 18. Jan. Zur Gesamtaufnahme - year:2020 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wec, Anna Z. [VerfasserIn] |
|---|
| Links: |
|---|
| doi: |
10.1101/395525 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI00033622X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI00033622X | ||
| 003 | DE-627 | ||
| 005 | 20230429084805.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200312s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/395525 |2 doi | |
| 035 | |a (DE-627)XBI00033622X | ||
| 035 | |a (DE-599)biorXiv10.1101/395525 | ||
| 035 | |a (biorXiv)10.1101/395525 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 570 |q DE-84 | |
| 100 | 1 | |a Wec, Anna Z. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Human antibody cocktail deploys multiple functions to confer pan-ebolavirus protection |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a During the unprecedented 2013–2016 Ebola virus disease (EVD) epidemic in Western Africa and in its aftermath, the passive administration of monoclonal antibodies (mAbs) emerged as a promising treatment approach1–7. However, all antibody-based therapeutics currently in advanced development are specific for a single member of the Ebolavirus genus, Ebola virus (EBOV), and ineffective against divergent outbreak-causing ebolaviruses, including Bundibugyo virus (BDBV) and Sudan virus (SUDV)2,3,5,7. Here we advance MBP134, a cocktail of two broadly neutralizing human mAbs targeting the filovirus surface glycoprotein, GP, as a candidate pan-ebolavirus therapeutic. One component of this cocktail is a pan-ebolavirus neutralizing mAb, ADI-15878, isolated from a human EVD survivor8,9. The second, ADI-23774, was derived by affinity maturation of a human mAb8,9 via yeast display to enhance its potency against SUDV. MBP134 afforded exceptionally potent pan-ebolavirus neutralization in vitro and demonstrated greater protective efficacy than ADI-15878 alone in the guinea pig model of lethal EBOV challenge. A second-generation cocktail, MBP134AF, engineered to effectively harness natural killer (NK) cells afforded additional, unprecedented improvements in protective efficacy against EBOV and SUDV in guinea pigs relative to both its precursor and to any mAbs or mAb cocktails tested previously. MBP134AF is a best-in-class mAb cocktail suitable for evaluation as a pan-ebolavirus therapeutic in nonhuman primates. | ||
| 700 | 1 | |a Bornholdt, Zachary A. |e verfasserin |4 aut | |
| 700 | 1 | |a He, Shihua |e verfasserin |4 aut | |
| 700 | 1 | |a Herbert, Andrew S. |e verfasserin |4 aut | |
| 700 | 1 | |a Goodwin, Eileen |e verfasserin |4 aut | |
| 700 | 1 | |a Wirchnianski, Ariel S. |e verfasserin |4 aut | |
| 700 | 1 | |a Gunn, Bronwyn M. |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Zirui |e verfasserin |4 aut | |
| 700 | 1 | |a Zhu, Wenjun |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Guodong |e verfasserin |4 aut | |
| 700 | 1 | |a Abelson, Dafna M. |e verfasserin |4 aut | |
| 700 | 1 | |a Moyer, Crystal L. |e verfasserin |4 aut | |
| 700 | 1 | |a Jangra, Rohit K. |e verfasserin |4 aut | |
| 700 | 1 | |a James, Rebekah M. |e verfasserin |4 aut | |
| 700 | 1 | |a Bakken, Russell R. |e verfasserin |4 aut | |
| 700 | 1 | |a Bohorova, Natasha |e verfasserin |4 aut | |
| 700 | 1 | |a Bohorov, Ognian |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Do H. |e verfasserin |4 aut | |
| 700 | 1 | |a Pauly, Michael H. |e verfasserin |4 aut | |
| 700 | 1 | |a Velasco, Jesus |e verfasserin |4 aut | |
| 700 | 1 | |a Bortz, Robert H. |e verfasserin |4 aut | |
| 700 | 1 | |a Whaley, Kevin J. |e verfasserin |4 aut | |
| 700 | 1 | |a Goldstein, Tracey |e verfasserin |4 aut | |
| 700 | 1 | |a Anthony, Simon J. |e verfasserin |4 aut | |
| 700 | 1 | |a Alter, Galit |e verfasserin |4 aut | |
| 700 | 1 | |a Walker, Laura M. |e verfasserin |4 aut | |
| 700 | 1 | |a Dye, John M. |e verfasserin |4 aut | |
| 700 | 1 | |a Zeitlin, Larry |e verfasserin |4 aut | |
| 700 | 1 | |a Qiu, Xiangguo |e verfasserin |4 aut | |
| 700 | 1 | |a Chandran, Kartik |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2020) vom: 18. Jan. |
| 773 | 1 | 8 | |g year:2020 |g day:18 |g month:01 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.chom.2018.12.004 |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/395525 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2020 |b 18 |c 01 | ||
| 953 | |2 045F |a 570 | ||